Author(s): Feryal Hashim


DOI: 10.52711/0974-360X.2022.00724   

Address: Feryal Hashim*
Department of Pharmaceutics, College of Pharmacy, Al-Nahrain University, Iraq.
*Corresponding Author

Published In:   Volume - 15,      Issue - 9,     Year - 2022

Adipokines are biologically effective substances released by adipose tissue and contributed for the management of many biological processes such as food intake, energy spending, adipocyte growing, tissue susceptibility to insulin, function of endothelium and many others. The modes of action of adipokines are autocrine or paracrine in adipocyte and endocrine in other tissues such as muscles, liver, and brain. Therefore, abnormal actions or levels of many adipokines may act as vinculum between corpulence, or cellular injury, and insusceptibility to insulin. Hereafter, the guidelines for the treatment of corpulence and related metabolic disorders may focus on the uses of drugs with adipokines agonist or antagonist properties, long acting, and less adverse effects.

Cite this article:
Feryal Hashim. Compendious Review on Adipokines of Corpulence. Research Journal of Pharmacy and Technology. 2022; 15(9):4315-8. doi: 10.52711/0974-360X.2022.00724

Feryal Hashim. Compendious Review on Adipokines of Corpulence. Research Journal of Pharmacy and Technology. 2022; 15(9):4315-8. doi: 10.52711/0974-360X.2022.00724   Available on:

1.    Rada FH. Platelet reactivity with a third generation thienopyridine drug versus with a second-generation thienopyridine drug. International journal of research in  Pharmaceutical sciences. 2020; 11(3): 3704-3709.
2.    Koushik Bhattacharya, Pallav Sengupta, Sulagna Dutta, Soumita Bhattacharya. Pathophysiology of Obesity: Endocrine, Inflammatory and Neural regulators. Research Journal of Pharmacy and Technology. 2020; 13(9):4469-4478. Doi:10.5958/0974-360X.2020.00789.1
3.    Jayamathi Govindaraj, Keerthidaa Govindaraj, S. Raghavendra Jayesh, Kesavaram Padmavathy, Mathangi Ramalingam, Vidyarekha U. Role of Adipokines in Obesity and Obesity related Metabolic Disorders. Research Journal of Pharmacy and Technology. 2021; 14(8):4261-4. DOI: 10.52711/0974-360X.2021.00739.  
4.    Ranjit Ambad, Roshan Kumar Jha, Dhruba Hari Chandi, Saurabh Hadke. Association of Leptin in Diabetes Mellitus and Obesity. Research Journal of Pharmacy and Technology. 2020; 13(12):6295-6299. DOI: 10.5958/0974-360X.2020.01095.1
5.    Rada FH. Impact of Osteoprotegerin and RANKL on Non-ST-segment Elevation Myocardial Infarction. International Journal of Nutrition, Pharmacology, Neurological Diseases. 2021;11:206-10. DOI:10.4103/ijnpnd.ijnpnd_30_21.
6.    R. Monalisa. Role of Leptin in obesity. Research Journal of Pharmacy and Technology .8(8): August, 2015; Page 1073-1076. DOI: 10.5958/0974-360X.2015.00185.7
7.    Radhika Bansal, Sriprajna Mayur, Usha Adiga, Sudheendrs Rao. Single Nucleotide Polymorphism of Leptin Receptor Gene in Type 2 Diabetes Mellitus: A Cross-sectional Study. Research Journal of Pharmacy and Technology . 2020; 13(2):560-564. DOI: 10.5958/0974-360X.2020.00105.5  
8.    Shahla O. Al-Ogaidi, Sura A. Abdulsattar, Hameed M. J. Al-Dulaimi. The Impact of Serum Leptin, Leptin Receptor and Insulin on Maternal Obesity. Research Journal of Pharmacy and Technology. 2019; 12(7): 3569-3574. DOI: 10.5958/0974-360X.2019.00609.7
9.    Haripriya Doraiswamy, Vijayalakshmi Kirshnamurthy. Cinnamaldehyde Inhibits Visceral Fat Accumulation and the levels of Glucose, Insulin, Leptin in Serum of rats fed with High Fat Diet (HFD). Research Journal of Pharmacy and Technology. 2015; 8(12): 1701-1706. DOI: 10.5958/0974-360X.2015.00306.6.
10.    Foo JP,Mantzoros CS.Leptin in congenital or HIV-associated lipodystrophy and metabolic syndrome: a need for more mechanistic studies and large, randomized, placebo-controlled trials. Metabolism. 2012; 61(10):1331–1336. DOI: 10.1016/j.metabol.2012.04.013
11.    Doaa Mahdi Omran, Saad Merza Alaraji, Ali Hussein Albayati, Wathiq Essam. Relationship between Ghrelin and Leptin with Insulin Resistance in Obese Patients and Non-Obese Individuals. Research Journal of Pharmacy and Technology . 2018; 11(1): 281-283. DOI: 10.5958/0974-360X.2018.00052.5   
12.    Hamed Mohsen, Haddad Shaden, AL Quobili Faiza, Hammoud Taghrid. Correlation of serum leptin levels with insulin resistance in Syrian obese patients with type 2 diabetes mellitus. Research Journal of Pharmacy and Technology .2013; 6(10): Page 1149-1151.
13.    Chou, K,Perry, CM. Metreleptin: first global approval. Drugs.2013, 73:989–997. doi: 10.1007/s40265-013-0074-7
14.    Ravussin E,Smith SR,Mitchell JA,Shringarpure R, Shan K, Maier H, et al. Enhanced weight loss with pramlintide/metreleptin: anintegrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring).2009; 17:1736–1743. doi: 10.1038/oby.2009.184.
15.    Wittamer V, Franssen JD, Vulcano  M,Mirjolet  JF,Poul  EL,Migeotte I, et al. Specifc recruitment of antigen-presenting cells by chemerin, a novel processed ligand  from human infammatory fluids. J Exp Med.2003;198: 977–985. doi: 10.1084/jem.20030382.
16.    Rada FH. Effect of Angiotensin II Receptor Blocker Treatment on Adipokine of Corpulence. Biomedical and Pharmacology Journal.2020;13(2) :957-963.
17.    Rada FH. Adequacy of Olmesartan monotherapy versus cotherapy in patients with essential hypertension. International journal of research in Pharmaceutical sciences .2020;11(2):1649-1654. DOI:
18.    Tianxin Sheng, Yunhe Lu, Kangjuan Yang, Yan Jin, Yinghua Wu, Zibo Zhang, YanhuaJin, XiongjiJin. Association Between Single Nucleotide Polymorphisms (SNPs) in the Promoter of Adiponectin Gene, Hypoadiponectinemia, and Diabetes. Research Journal of Science and Technology. 2016; 8(1): 34-40. DOI: 10.5958/2349-2988.2016.00004.8
19.    Rada FH. Association of lipid fractions levels with cardiovascular disease. Asian Journal of Pharmaceutical and Clinical Research.2017; 10(3) :180-182. DOI:
20.    Okamoto M,Ohara-Imaizumi M, Kubota N,Hashimoto S,Eto K,Kanno T, et al.  Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration. Diabetologia.2008; 51(5):827–835. doi: 10.1007/s00125-008-0944-9.
21.    Tullin S, Sams A, Brandt J, Dahl K, Gong W, Jeppesen CB, et al. Recombinant adiponectin does not lower plasma glucose in animal models of type 2 diabetes. PLOS ONE.2012; 7:e44270.
22.    Okada-Iwabu M, Iwabu M, Ueki K,Yamauchi T,  Kadowaki T. Perspective of Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity.Diabetes Metabolism Journal. 2015 Oct;39(5):363-72. doi: 10.4093/dmj.2015.39.5.363.
23.    Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, et al. Nampt/ PBEF/ Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metabolism.2007; 6:363–375. doi: 10.1016/j.cmet.2007.09.003.
24.    Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD (+) intermediate, treats the pathophysiology of diet-and age induced diabetes in mice. Cell Metab.2011; 14:528–536.  doi: 10.1016/j.cmet.2011.08.014.
25.    Alexander RW. Understanding adipose-derived stromal vascular fraction (ad-SVF) cell biology and use on the basis of cellular, chemical, structural and paracrine components: A concise review. Journal of Prolotherapy. 2012; 4:e855–e869.
26.    Rada FH.Antiplatelet adequacy of cyclopentyl triazolopyrimidine versus clopidogrel in patients with coronary heart disease . Asian Journal of Pharmaceutical and Clinical Research.2018;11(12) :536-539.
27.    Li K, Li L,Yang M, Liu H,Liu D, Yang H, et al. Short-term continuous subcutaneous insulin infusion decreases the plasma vaspin levels in patients with type 2 diabetes mellitus concomitant with improvement in insulin sensitivity. European Journal of Endocrinology.2011; 164:905– 10. doi: 10.1530/EJE-10-1023.
28.    Youn BS, Klöting N, Kratzsch J, Lee N, Park JW, Song ES, et al. Serum vaspin concentrations in human obesity and Type 2 diabetes. Diabetes.2008; 57: 372–377.doi: 10.2337/db07-1045.
29.    Klöting N, Kovacs P, Kern M, Heiker JT, Fasshauer M, Schön MR, et al. Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia.2011; 54:1819–1823. doi: 10.1007/s00125-011-2137-1.
30.    Nauck MA.Incretin-based therapies for Type 2 diabetes mellitus: properties, functions, and clinical implications. American Journal of Medicine. 2011; 124:S3–S18. doi: 10.1016/j.amjmed.2010.11.002.
31.    Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, et al.  Dipeptidyl-peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes.2011; 60:1917–1925. doi: 10.2337/db10-1707
32.    Sell H,Blüher M, Klöting N, Schlich R, Willems M, Ruppe F, et al.Adipose dipeptidylpeptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue invivo and invitro. Diabetes Care.2013; 36:4083–4090. doi: 10.2337/dc13-0496

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available